Table 2.
Characteristics of eligible studies
| Study | Year | Country | Study design | Patient | HPD | Incidence of HPD | Overall survival | NOS |
|---|---|---|---|---|---|---|---|---|
| Ferrara R [7] | 2018 | France | Retrospective | 406 | 56 | 13.79% |
HPD vs. PD without HPD (HR 2.18, 95% CI (1.29–3.69), p = 0.03) |
6 |
| Lo Russo G [15] | 2018 | Italy | Retrospective | 152 | 39 | 25.66% |
HPD vs. non-HPD (4.4 vs. 17.7 months) |
6 |
| Tunali I [16] | 2019 | USA | Retrospective | 187 | 15 | 8.02% |
HPD vs. PD without HPD (3.2 vs. 8.4 months, p < 0.001) |
6 |
| Kim CG [13] | 2019 | Korea | Retrospective | 263 | 54 | 20.53% |
HPD vs. PD without HPD (HR 5.71, 95% CI 3.14–8.23, p < 0.05) |
6 |
| Kim Y [14] | 2019 | Korea | Retrospective | 335 | 48 | 14.33% |
HPD vs. PD without HPD (HR 1.9, 95% CI 1.2–3.0, p = 0.006) |
6 |
| Castello A [17] | 2019 | Italy | Retrospective | 46 | 14 | 30.43% |
HPD vs. non-HPD (4 vs. 15 months, p = 0.003) |
6 |
HPD hyperprogressive disease, NOS Newcastle–Ottawa Scale, PD progressive disease at the first response evaluation after treatment, USA the United States